Evaluation of fluorescence‐guided surgery agents in a murine model of soft tissue fibrosarcoma

Background and Objectives Soft tissue sarcomas (STS) are mesenchymal malignancies. Treatment mainstay is surgical resection with negative margins ± adjuvant treatment. Fluorescence‐guided surgical (FGS) resection can delineate intraoperative margins; FGS has improved oncologic outcomes in other mali...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of surgical oncology 2018-05, Vol.117 (6), p.1179-1187
Hauptverfasser: Prince, Andrew C., McGee, Andrew S., Siegel, Herrick, Rosenthal, Eben L., Behnke, Nicole K., Warram, Jason M.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Background and Objectives Soft tissue sarcomas (STS) are mesenchymal malignancies. Treatment mainstay is surgical resection with negative margins ± adjuvant treatment. Fluorescence‐guided surgical (FGS) resection can delineate intraoperative margins; FGS has improved oncologic outcomes in other malignancies. This novel strategy may minimize resection‐associated morbidity while improving local tumor control. Methods We evaluate the tumor‐targeting specificity and utility of fluorescence‐imaging agents to provide disease‐specific contrast. Mice with HT1080 fibrosarcoma tumors received one of five probes: cetuximab‐IRDye800CW (anti‐EGFR), DC101‐IRDye800CW (anti‐VEGFR‐2), IgG‐IRDye800CW, the cathepsin‐activated probe Prosense750EX, or the small molecule probe IntegriSense750. Tumors were imaged daily using open‐ and closed‐field fluorescence imaging systems. Tumor‐to‐background ratios (TBR) were evaluated. On peak TBR days, probe sensitivity was evaluated. Tumors were stained and imaged microscopically. Results At peak, closed‐field imaging TBR of cetuximab‐IRDye800CW (16.8) was significantly greater (P 
ISSN:0022-4790
1096-9098
DOI:10.1002/jso.24950